| __timestamp | Amphastar Pharmaceuticals, Inc. | Dr. Reddy's Laboratories Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 56369000000 |
| Thursday, January 1, 2015 | 174172000 | 62786000000 |
| Friday, January 1, 2016 | 150976000 | 62427000000 |
| Sunday, January 1, 2017 | 149380000 | 62453000000 |
| Monday, January 1, 2018 | 187681000 | 65724000000 |
| Tuesday, January 1, 2019 | 190434000 | 70421000000 |
| Wednesday, January 1, 2020 | 206506000 | 80591000000 |
| Friday, January 1, 2021 | 238029000 | 86645000000 |
| Saturday, January 1, 2022 | 250127000 | 100551000000 |
| Sunday, January 1, 2023 | 293274000 | 42907000000 |
| Monday, January 1, 2024 | 115557000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for two prominent players: Dr. Reddy's Laboratories Limited and Amphastar Pharmaceuticals, Inc., from 2014 to 2023.
Dr. Reddy's Laboratories consistently demonstrates a robust cost structure, with an average cost of revenue around 73 billion USD, peaking at 116 billion USD in 2024. This reflects a strategic focus on optimizing production and distribution processes. In contrast, Amphastar Pharmaceuticals, with a more modest average of 200 million USD, shows a steady increase, culminating in a 47% rise from 2014 to 2023.
The data highlights Dr. Reddy's dominance in scale and efficiency, while Amphastar's growth trajectory suggests a promising future. Missing data for 2024 indicates potential volatility, warranting close monitoring by investors and stakeholders.
Cost of Revenue Trends: Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Incyte Corporation vs Dr. Reddy's Laboratories Limited
Cost of Revenue: Key Insights for Insmed Incorporated and Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Pharming Group N.V.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Wave Life Sciences Ltd.
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Amphastar Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Mesoblast Limited vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Galapagos NV